The United States Patent and Trademark Office (USPTO) has issued patent US12582723B2, titled 'Polynucleotides encoding a human FKRP protein,' to Genethon. The patent covers synthetic polynucleotides that encode a human fukutin-related protein (FKRP) and include specific mutations to prevent supplementary transcripts from frameshift start codons. These polynucleotides are intended for therapeutic use, particularly in treating conditions arising from FKRP deficiency or defects in alpha-dystroglycan glycosylation, such as Limb-Girdle Muscular Dystrophy type 2I (LGMD2I).

This patent grant signifies a new intellectual property right for Genethon concerning specific genetic therapies. While this is a patent grant and not a regulatory rule imposing direct compliance obligations on other entities, it may impact research and development activities in the biotechnology and pharmaceutical sectors. Companies operating in this space, particularly those developing therapies for muscular dystrophies or related glycosylation disorders, should be aware of this patent's claims to ensure they do not infringe upon the granted intellectual property rights. No immediate compliance actions are required for entities not directly involved with the patented technology, but legal counsel should be consulted for any potential overlap with ongoing or planned research and development.